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We have characterized the ability of adeno-associated 
virus (AAV) serotypes 1–9 in addition to nineteen novel 
vectors isolated from various tissues, to transduce mouse 
and human ciliated airway epithelium (HAE). Vectors 
expressing α-1-antitrypsin (AAT) and β-galactosidase 
were co-instilled into the mouse lung. Of all the vectors 
tested rh.64R1, AAV5 and AAV6 were the most efficient. 
The high transduction observed in mouse was repro-
duced in HAE cell cultures for both rh.64R1 and AAV6 
but not for AAV5. Since AAV6 was the most efficient 
vector in mouse and HAE we also tested the transduc-
tion efficiencies of the AAV6 singleton vectors (i.e., AAV6 
variants with targeted mutations) in these models. Of 
these, AAV6.2 transduced mouse airway epithelium and 
HAE with greater efficiency than all other AAV vectors 
tested. We demonstrated that AAV6.2 exhibits improved 
transduction efficiency compared to previously reported 
AAVs in mouse airways and in culture models of human 
airway epithelium and that this vector requires further 
development for preclinical and clinical testing.
Received 7 August 2008; accepted 24 October 2008; published online  
9 December 2008. doi:10.1038/mt.2008.261
IntroductIon
Delivery of therapeutic genes to the diseased airway epithelium 
in vivo is a promising option for the genetic treatment of vari-
ous lung diseases that include cystic fibrosis (CF) airway disease, 
α-1-antitrypsin (AAT) deficiency, chronic obstructive pulmonary 
disease and pulmonary hypertension.1–3 Of the many viral gene 
therapy vectors, adeno-associated virus (AAV)-based vectors 
hold great promise for efficiently targeting airway epithelium in 
vivo.3 AAV is a single-stranded DNA virus that belongs to the 
Parvoviridae family4 and is characterized by its safety, low toxicity, 
and its ability to confer long-term stable transgene expression.5–7 
Furthermore, since AAV can transduce non-dividing cells8 its use 
in lung is warranted as <1% of airway epithelial cells are actively 
dividing.9 AAV vectors have been developed for CF airway gene 
therapy10–12 with AAVs 1, 5, and 6 transducing murine conducting 
airway and cultures of human ciliated airway epithelium (HAE) 
with varying efficiencies.10,12–16. However, efforts to replace a func-
tional copy of the CF gene (CFTR17) to the lungs of CF patients 
using AAV2-based vectors have proven a significant challenge. 
Indeed, while AAV-based vectors expressing CFTR can be deliv-
ered safely to the lungs of CF patients, efficacy data have been 
disappointing.18–23 To date, no correction of the bioelectric CF 
defect or reversal of CF pathology has been described. The devel-
opment of alternative AAV serotypes is a promising strategy to 
improve lung-directed AAV-mediated gene transfer.
Since 2002, the AAV vector pipeline has been greatly enriched 
with the identification of novel AAV vector serotypes isolated from 
various species including caprine, avian, bovine, nonhuman primate 
and human.24–26 Specifically, >110 novel AAV vector isolates have 
been identified in various tissues derived from human and nonhu-
man primate.25,26 This effort was undertaken to further understand 
AAV natural ecology as well as novel biology that could improve 
vector technology. A safe and efficacious AAV vector is presumed 
to be defined by the capsid, which also impacts on gene transfer tro-
pism, gene transfer efficiency, immune activation, and susceptibil-
ity. Thus, we have focused on defining particular AAV capsids that 
fulfill our criteria for candidate gene transfer vectors for the lung.
Here, we build on the existing vector discovery25 by optimi-
zation and characterization of nineteen novel AAV vectors from 
isolates that are representative members of Clades A–F, as well as 
known serotypes AAVs 1, 2, 5, 6, 7, 8, and 9 on relevant in vivo and 
in vitro model systems of the human airway epithelium.
results
AAV-mediated transduction of mouse lung airway 
epithelium in vivo
AAV vectors expressing human AAT (hAAT) or nLacZ using the 
chicken-β-actin promoter were screened initially in the mouse 
lung in a single-blinded manner. Using a vector co-instillation 
strategy we determined the ability of the candidate AAV vectors 
to transduce the mouse lung by measuring hAAT secretion over 
time in the serum and evaluating tropism for conducting airway 
versus alveolar epithelium by nLacZ expression. A mixture of 
AAV vectors expressing hAAT and nLacZ were administered to 
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mice (n = 15) by intratracheal instillation. Twenty-eight days later, 
mice were killed and sera analyzed for hAAT concentration and 
lung tissue evaluated for nLacZ expression. Based on hAAT serum 
concentrations, the 19 candidate vectors, including the well estab-
lished serotypes AAV1, 2, 5, 6, 7, 8, and 9, were segregated into 
three groups of expression levels (high, medium, and low). The 
high-expressors group conferring hAAT concentrations in serum 
>1,500 ng hAAT/ml serum were serotypes AAV1, 6, 9, and novel 
vectors rh.8, rh.10, rh.20, rh.46, rh.64R1, hu.48R3, and cy.5R4 
(Figure 1a). In the medium-expressors group with 500–1,500 ng 
hAAT/ml serum were serotypes AAV7, 8 and novel vectors rh.2R, 
rh.32.33, rh.64R2, hu.13, hu.32, hu.37, and pi.2. Of note is the 
observation that both high and medium expressors all generated 
significantly higher hAAT levels than produced by AAV2 or AAV5 
(P < 0.05, analysis of variance, Student–Newman–Keuls test, n = 
15). In the low-expressors group (<500 ng/ml hAAT) including 
AAV2 and AAV5, the novel vectors rh.39, rh.43, hu.11, hu.29R, 
and hu.51 produced very low levels of hAAT which approximated 
the detection sensitivity of the hAAT ELISA.
Histochemical analyses of mouse lungs for β-galactosidase 
activity revealed that the candidate AAV vectors demonstrated dis-
tinct targeting patterns of transduction for either conducting air-
way and/or alveolar epithelium with varying degrees of efficiency 
(Figure 1b). AAVs 1, 5, and 6 have been previously shown to target 
mouse conducting airway in addition to alveolar epithelium10,11,13,14 
while AAV9 vectors preferentially transduce alveolar epithelium.14 
Quantitation of the number of cells of the conducting airways and 
alveolar cells expressing nLacZ provided a rank order of AAV vec-
tors with AAV6 and AAV5 being the most efficient and closely 
followed by AAV1, rh.64R1, hu.48R3, and rh.10 (Figure 1b). The 
transduction profile in lung varied significantly between differ-
ent AAV vectors. For AAV2 and hu.29R no transduced cells were 
detected in the conducting airway and very few or no transduced 
cells detected in the alveolar epithelium. LacZ transduction pro-
files correlated well with hAAT expression levels from the same 
animals, as highlighted by the consistently poor performance of 
AAV2 and hu.29R while the AAV6, AAV1, rh.10, hu.48R3, and 
rh.64R1 vectors (presented in descending order of nLacZ trans-
duction efficiency) efficiently transferred genes to conducting air-
ways. In addition, we found tropism differences for conducting 
airway and alveolar epithelium with the AAV6 vector targeting 
both these cell populations with almost equal efficiency whereas, 
AAV1, rh.10, hu.48R3, and rh.64R1 exhibited a preference for 
conducting airway (Figures 1b and 2a). AAV9 and rh.8 showed 
high systemic concentrations of hAAT and LacZ transduction was 
limited to alveolar epithelium. For vectors that expressed either 
low levels of hAAT (hu.51, hu.29R, hu.11, rh.39, and rh.43), or 
moderate hAAT levels (AAV7, AAV8, hu.13, hu.37, rh.64R2, pi.2, 
hu.32, rh.2R, and rh.32.33), nLacZ transduction was observed in 
the alveolar epithelium but at very low amounts. We found no cor-
relation of hAAT and nLacZ gene transfer for rh.20 and cy.5R4, 
which both expressed high hAAT levels, but resulted in low nLacZ 
transduction efficiency of alveolar epithelium only.
AAV-mediated nlacZ transduction of mouse nasal 
airway epithelium in vivo
The mouse nasal airway epithelium most closely resembles the 
epithelium of the human conducting airways in terms of cell 
composition and ion transport properties.27,28 We evaluated the 
performance of all the candidate AAV vectors in the mouse nasal 
airway epithelium. Mice (n = 5/group) were inoculated intra-
nasaly with 1011 genome copies of each AAV vector expressing 
nLacZ. En face examination of gross sections of the nasal pas-
sages was performed 28 days later. At this time point, the trans-
duction profile for many of the AAV vectors was not similar to 
that previously shown for mouse lung. In fact, only AAVs 5, 6, 9, 




















































































































































































































































































































Figure 1 transduction efficiency of the AAV vectors in model sys-
tems of airway epithelium. (a) hAAT expression (ng/ml) in serum 
28 days following a single dose of 1011 genome copies of AAV vectors 
expressing hAAT. Results are presented as the average of n = 15 ± SD. 
(b) nLacZ gene transfer was quantitated by counting the number of 
nLacZ positive cells in mice treated with all vectors. Values presented 
as the average of n = 15 ± SD. Filled columns represent cells of the 
conducting airways and open columns represent cells of the alveolar 
epithelium. (c) GFP gene transfer was quantitated in representative 
images using the Image J software. Results are presented as the average 
of n = 8 (two cultures per vector, repeated four times) ± SD. Vectors are 
grouped in Clades A–F with the exception of the outliers rh.32.33, rh.8, 
and AAV5. *High transducers, **medium transducers, P < 0.05, analysis 
of variance, Student–Newman–Keuls test.
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 epithelium (Figure 3). Since the AAV vectors that transduced the 
nasal airway epithelium did not target olfactory epithelium we 
quantitated gene transfer only in the respiratory and transitional 
epithelium by counting nLacZ expressing cells in three standard 
cross  sections (Figure 3). AAV6 and AAV5 transduced the nasal 
airway epithelium most efficiently and were statistically more 
efficient than rh.64R1, rh.64R2, and AAV9 (P < 0.05, analysis of 
variance, Student–Newman–Keuls test).
AAV-mediated GFP transduction of human airway 
epithelium cultures in vitro
The discrepancies in the transduction efficiency of the candidate 
AAV vectors in the epithelium of the mouse nose and mouse lung 
highlights the limitation of using these models to evaluate AAV 
vectors for human lung use and prompted the assessment of the 
candidate AAV vectors in more relevant models of human airway 
epithelium. In vitro models of HAE are accepted to recapitulate 
key aspects of the human conducting airway epithelium in terms 
of cell composition, tight junction formation and the formation 
of an overlaying airway surface liquid layer.29 In a double-blinded 
fashion, all our candidate AAV vectors  (expressing GFP) were 
applied to the apical surface of HAE (two cultures per  vector) using 
cells derived from a total of four patients. Using several different 
production lots of the AAV vectors representative transduction 
efficiency data seven days after vector inoculation are presented 
in Figure 2b. Based on GFP expression, vectors were scored as 
2/1 2/6 22/hu.48R3 2/hu.13 2/hu.51
2/hu.29R 2/7 2/cy.5R42/hu.11 2/8 2/hu.37





2/1 2/6 22/hu.48R3 2/hu.13 2/hu.51
2/hu.29R 2/7 2/cy.5R42/hu.11 2/8 2/hu.37





Figure 2 AAV-mediated-transgene expression in models of airway epithelium. (a) nLacZ gene transfer to mouse lung was assessed by his-
tochemical analysis. Sections were counterstained with nuclear fast red and representative images taken at ×200 were chosen based on regions 
predominately showing LacZ transduction. Representative images of n = 15 mice are shown. (b) Transduction efficiency of AAV vectors in cultures 
of HAE. En face view of GFP-mediated gene transfer to HAE 7 days after apical inoculation of 1011 genome copies. Representative images of n = 8 
cultures taken at ×5 are shown.
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high-, medium-, or low-transducers. XZ confocal analysis dem-
onstrated the presence of GFP ciliated and nonciliated cells in 
cultures infected with either the high- or medium-transducers 
(data not shown). The high-transducing vector group included 
AAV6, hu.13, hu.37, rh.2R, rh.10, rh.64R1, and rh.8 (Figures 
1c and 2b). The medium-transducing group was comprised of 
AAV1, hu.48R3, hu.51, hu.29R, rh.39, rh.20, rh.46, rh.64R2, rh.43, 
and rh.32.33 (Figures 1c and 2b). The low-transducing group 
included hu.11, cy.5R4, pi.2, and AAV9 (Figures 1c and 2b). Very 
few positive GFP cells were seen in HAE inoculated with AAVs 2, 
7, 8, hu.32 and AAV5 (Figures 1c and 2b).
evaluation of the AAV6-based singleton AAV vectors
The consistent superior performance of AAV6 in the epithelial 
cells of mouse lung (Figures 1b and 2a), mouse nose (Figure 3) 
and HAE (Figure 2b) prompted the evaluation of the AAV6 sin-
gleton mutants in these model systems.30,31 Briefly, the AAV6.1 
vector was created by mutating the lysine (K) residue at position 
531 to glutamic acid (E) ablating the heparin binding motif. The 
AAV6.2 vector mutant was created by mutating the phenyalanine 
(F) residue at position 129 to leucine (L), maintaining the hepa-
rin binding motif. The K and the F residues were also mutated 
together to create the AAV6R2 vector.
The efficiencies of AAV6 and the singleton mutants were 
tested in mouse lungs following an intratracheal co-instillation of 
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Figure 4 transduction efficiency of AAV6 vector singleton mutants. (a) nLacZ gene transfer to mouse lung was assessed by histochemical analysis 
of the AAV6.1, AAV6.2, and AAV6R2 vector-treated mouse lungs. Representative images of n = 15 mice taken at ×100 are shown. (b) The number 
of nLacZ positive cells was quantitated and is presented as the average of n = 15 ± SD. Open columns represent epithelial cells of the conducting 
airways and filled columns represent epithelial cells of the alveolus. (c) hAAT expression (ng/ml) in serum 28 days following a single dose of 1011 
genome copies of the AAV6 singleton mutant vectors expressing hAAT. Results are presented as the average of n = 15 ± SD. (d) En face view of GFP-
gene transfer to HAE mediated by AAV6.1, AAV6.2, and AAV6R2 7 days after inoculation. (e) XZ confocal image of AAV6.2 inoculated HAE with cilia 
immunostained red (see Materials and Methods for detail). Both ciliated and nonciliated cells were transduced by AAV vectors. (f) Hematoxylin–eosin 
































Figure 3 AAV-mediated-nLacZ gene transfer to mouse nose. The 
number of nLacZ positive cells was quantitated and is presented as 
the average of n = 5 ± SD. *P < 0.05, analysis of variance, Student–
Newman–Keuls test.
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to those described earlier. Compared to the parent AAV6 vector 
the AAV6.1 vector maintained tropism for conducting airway 
and alveolar epithelium (Figure 4a) but its transduction effi-
ciency was severely hampered. Interestingly, the transduction 
efficiency of AAV6.1 resembled that of AAV1 (Figures 1 and 2). 
The  transduction efficiency of AAV6.2 in mouse conducting air-
way (Figure 4a) and nasal airway (Figure 3) was superior to any 
other vector and was statistically better than AAV6, AAV6.1, and 
AAV6R2 (P < 0.05, analysis of variance, Student–Newman–Keuls 
test). AAV6.2 also produced the highest amount of hAAT in 
serum compared to all the other AAV vectors, including AAV6.1 
and AAV6R2 (Figures 1a and 4c). Although AAV6.2 was signifi-
cantly better than AAV6 in generating hAAT, the difference in 
transduction efficiency was not as dramatic as that observed by 
nLacZ transduction.
The AAV6 vector singletons were tested on HAE and we found 
that both AAV6.1 and AAV6R2 resulted in low transduction effi-
ciency (Figure 4d) similar to that produced by AAV5, hu.11 and 
hu.32 (Figures 1c and 2b). However, AAV6.2 consistently resulted 
in almost 20% GFP transduction (3.12 ± 0.86 × 107 relative fluo-
rescence units, n = 8) of luminal epithelial cells in cultures derived 
from six different patients. Both ciliated and nonciliated epithelial 
cells were detected as GFP-positive by XZ confocal microscopy, 
(Figure 4e). AAV6.2 was consistently more efficient than AAV6 at 
transducing HAE (Figures 1c and 2b).
dIscussIon
To identify candidate AAV vectors for pre-clinical and clinical 
assessment for diseases of the lung we have characterized novel 
AAV vectors isolated from different tissues including human and 
nonhuman primates. Nineteen novel or engineered AAV vectors 
representing members of Clades A–F and several Clade outliers 
(rh.8, rh.32.33, and AAV5) were evaluated in relevant airway epi-
thelium model systems. These studies revealed that AAV capsid 
structure has a significant impact on airway transduction efficiency 
and tropism for conducting airway and/or alveolar epithelium.
Overall, Clade A–based vectors were the most efficient at 
transducing the mouse conducting airway with AAV6 and the 
singleton mutant AAV6.2 (F129L) performing the best. The abil-
ity of AAV6 to bind to heparin has been implicated in improved 
binding, but not uptake, by airway epithelial cells.10 Surprisingly, 
competition experiments have demonstrated that heparin bind-
ing on AAV6 is not required for infection.10 Indeed, in our studies 
we found that for AAV6.2, which maintained heparin binding, 
there was increased transduction in all model systems studied, 
suggesting that binding was significantly improved. Preservation 
of the AAV6 heparin binding domain has also been shown to be 
important in sustaining efficient transduction of mouse  liver.31 
Ablation of the heparin binding motif in the AAV6 singleton 
mutants, AAV6.1 and AAV6R2, was detrimental to efficient gene 
transfer to mouse airways and HAE. Indeed, capsids from other 
Clade A viruses, that lack the lysine residue at position 531 impli-
cated in heparin binding,31 including AAV1, hu.48R3, AAV6.1, 
and AAV6R2, were significantly less efficient at transducing the 
conducting airways and HAE compared to AAV6 and AAV6.2. 
Although Clade A vectors efficiently produced high levels of 
hAAT protein following intratracheal instillation to lung, a clear 
correlation with respect to heparin binding and transduction 
of alveolar and nasal airway epithelium was highlighted. The 
heparin binders AAV6 and AAV6.2 transduced the alveolar and 
nasal airway epithelium efficiently while the nonheparin binders 
AAV1, hu.48R3, AAV6.1, and AAV6R2 were inefficient in these 
tissues.
In contrast, Clade B vectors, which include the prototype 
AAV2, contrary to previous reports12 failed to transduce mouse 
conducting and HAE and also did not transduce the mouse nasal 
airway. Similarly, hu.51 (ref. 32), an AAV2-like vector that binds 
heparin, was also inefficient in all model systems tested. However, 
hu.13 and hu.29R (which do not bind heparin) did transduce HAE 
with good efficiency. Hu.13 and hu.51 (which bind heparin) also 
transduced, albeit at low levels, mouse alveolar epithelium poten-
tially explaining the low to moderate levels of serum hAAT pro-
tein levels measured with these vectors. In this instance, absence 
of heparin binding significantly improved the vector transduction 
profile in HAE. The stark contrast of the impact of heparin affin-
ity on transduction efficiency between Clade A and Clade B vec-
tors demonstrates the context dependent requirements for AAV 
permissivity.
We only evaluated one vector representing Clade C, hu.11. 
This vector poorly transduced mouse alveolar epithelium and 
HAE. Members of Clade F transduced mouse alveolar epithelium 
with moderate (hu.32) to good (AAV9) efficiency but were poorly 
efficient in HAE. The difference in performance between hu.32 
and AAV9 is interesting since they only differ structurally within 
the VP12-unique domains and have identical VP3 domains on 
their capsid. The most inconsistent transduction patterns in lung 
were seen with vectors of Clade E, which includes AAVs 7 and 8. 
Most of the vectors evaluated resulted in moderate to good serum 
hAAT protein expression and with the exception of rh.39, all vec-
tors transduced mouse alveolar epithelium with rh.64R1 being 
the most efficient. Rh.10 and rh.64R1 were as efficient as AAV1 
at transducing the mouse conducting airway and HAE. Rh.64R1 
and rh.64R2 were the only Clade E members that transduced 
the mouse nasal airway epithelium. Interestingly, while rh.64R2 
transduced the nasal airway epithelium it failed to transduce con-
ducting airway suggesting that even slight changes to the capsid 
structure can affect cell tropism.
AAV5 has been shown to effectively target the mouse con-
ducting and nasal airway epithelium;12–14 however in contrast to 
the findings of Zabner and colleagues,12,15 we found that AAV5 
was poorly efficient when applied apically to HAE. AAV5 was 
also shown to be significantly more effective at transducing 
mouse conducting airway than AAV1,13 which is in agreement 
with our findings in mouse airway and HAE. In a different study 
comparing AAV1 and AAV5 in mouse lung, Virella-Lowell and 
colleagues demonstrated that AAV1 did not efficiently transduce 
mouse conducting airways.16 However, the authors did show 
that AAV1 and AAV5 were equally efficient in mouse lung using 
luminescence as a readout.16 The disadvantage of luminescence 
imaging is that it does not distinguish vector tropism such as 
differential transduction of conducting airways and alveolar epi-
thelium. Seiler and colleagues have shown that AAV6 was more 
effective than AAV5 at transducing mouse conducting  epithelium 
in vivo.15
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Discrepancies in transduction efficiencies between the model 
systems we have tested serves to highlight the difficulty in pre-
dicting the usefulness of gene transfer vectors for human use. 
Without testing vectors in several relevant model systems caution 
is required in identifying the appropriate vectors to carry into pre-
clinical development. We have attempted to use the most accepted 
and most relevant model systems of the airway epithelium for our 
studies including the mouse upper and lower airways in vivo and 
HAE in vitro. The use of these models has led to the identification 
of AAV6.2 as the most efficacious AAV vector that can now be 
carried into further preclinical and possibly clinical testing.
A challenge in the development of lung-directed gene transfer 
for humans has been the uncertainty of the relevance of the differ-
ent model systems of airway. Most studies utilize the mouse lung 
to assess gene transfer agents although the mouse nasal epithelium 
is proposed to most represent the morphology and physiology of 
the human conducting airway epithelium.14,33 While rabbits and 
macaques have been used for lung-directed gene transfer studies, 
species susceptibility to virus-based vector-mediated transduc-
tion has limited their wide application.3,34–36 However, it is clearly 
important to exercise caution when translating findings from ani-
mal models to predictions for promising vectors in clinical trials. 
table 1 decision matrix for selection of lead AAV vector candidates
clade capsid
Mouse lung Mouse nose Human airway cultures
score
LacZ gene expression
hAAT gene  
expression LacZ gene expression GFP gene expressionconducting Airways Alveoli
WP 2 WP 1 WP 2 WP 3 WP 4
A AAV1 2 1 3 — 2 19
 hu.48R3 2 1 3 — 2 19
AAV6 4 3 4 3 2 36
 AAV6.2 5 5 5 4 4 53
 AAV6.1 2 1 3 — 0.5 13
 AAV6R2 2 1 3 — 0.5 13
B AAV2 — — 1 — — 2
 hu.13 — 1 2 — 2 13
 hu.51 — 1 1 — 1 7
 hu.29R — — 1 — 2 10
C hu.11 — 1 1 — 0.5 5
D AAV7 — 1 2 — 0.5 7
 cy.5R4 — 1 3 — 0.5 9
E AAV8 — 1 2 — 0.5 7
 hu.37 — 1 2 — 2 13
 rh.39 — — 1 — 0.5 4
 rh.2R — 1 2 — 2 13
 rh.10 2 1 3 — 2 19
 rh.20 2 1 3 — 2 19
 rh.46 — 1 3 — 0.5 9
 rh.64R1 2 1 2 2 2 23
 rh.64R2 — 1 2 2 0.5 13
 pi.2 1 1 2 — 0.5 9
 rh.43 — 1 1 — 2 11
F AAV9 — 2 3 2 0.5 16
 hu.32 — 1 2 — 1 9
rh.32.33 — 1 2 — 0.5 7
rh.8 — 1 3 — 2 15
AAV5 3 3 1 3 0.5 22
The model systems on which the adeno-associated virus (AAV) vectors were assessed were assigned a weighted parameter (WP) number based on their relevance to 
human conducting airway. The greater their relevance to human airway, the higher the weighted parameter number. Human ciliated airway epithelium (HAE) closely 
models human conducting airway and was assigned the highest weighted parameter of 4 followed by mouse nasal airway that was assigned a weighted parameter 
of 3 and mouse conducting airway transduction that was assigned a weighted parameter of 2. AAV-mediated human α-1-antitrypsin expression following delivery to 
lung was assigned a weighted parameter of 2. Mouse alveolar epithelium was given the lowest weighted parameter of 1. The final score was calculated by the addition 
of scores based on the performance of AAV vectors on each model system after multiplication by the weighted parameter. Maximum score based on superior vector 
performance on all model systems is 60.
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The in vitro model of HAE bring us one step closer to studying 
gene transfer vectors in human airways in vivo since these models 
recapitulate key aspects of the human conducting airway epithe-
lium cell composition and physiology. We discovered that AAV 
vectors (i.e., rh.2R, hu.13, hu.29R) that did not transduce mouse 
nasal epithelium or were poorly efficient in mouse lung were as 
effective as AAV6 at transducing HAE. These findings clearly 
exemplify the need to evaluate gene transfer agents in different 
but relevant model systems of the airway to grade AAV vectors for 
selection of lead clinical vector candidates.
The current in vivo and in vitro model systems of the airway 
represent certain aspects of the human conducting airway. In an 
effort to identify an AAV vector for preclinical and possibly clini-
cal testing it became apparent that much like the field of small 
molecule drug screening, it is crucial to assess the performance 
of vectors in multiple model systems. Here, we propose a deci-
sion matrix based on criteria that identify lead vectors for lung 
directed gene transfer. While there are obvious limitations to all of 
the model systems we used (mouse nose, mouse lung or cultures 
of HAE) taken together they can provide invaluable insight into 
vector biology and tropism. Weighted parameters were used in a 
decision making algorithm to reflect the importance or relevance 
of certain model systems more appropriately. In the context of our 
studies and the models of airway epithelium that we evaluated, 
HAE closely models human conducting airway and as such, was 
assigned the highest weighted parameter of 4. Mouse nasal airway 
was assigned a weighted parameter of 3 and mouse conducting 
airway a weighted parameter of 2. Interestingly, using hAAT in 
mouse lung was frequently indicative of the transduction effi-
ciency of vectors in HAE and as such, was assigned a weighted 
parameter of 2. nLacZ transduction of mouse alveolar epithelium 
was given the lowest weighted parameter of 1 (Table 1). The gene 
transfer efficiency of the AAV vectors in each model system was 
scored on a scale of 1–5 (5 being the most efficient). Using this 
decision matrix, and the weighted parameter values assigned to 
each model system we found AAV6.2 to be the most promising 
AAV vector for human conducting airway transduction. In brief, 
as shown in Table 1, AAV6.2 scored 5 for nLacZ transduction of 
mouse conducting airway (score 5 × 2 = 10), 5 for nLacZ trans-
duction of mouse alveolar epithelium (score 5 × 1 = 5), 5 for hAAT 
expression (score 5 × 2 = 10), 4 for nLacZ transduction of mouse 
nasal airway (score 4 × 3 = 12) and 4 for GFP transduction of HAE 
(score 4 × 4 = 16), and was assigned a total score of 53 [(10) + 
(5) + (10) + (12) + (16)] from a maximum of 60. We propose that 
AAV6.2 has fulfilled the requirements that warrant this vector 
being taken further into testing for potential AAV gene therapeu-
tics for CF lung disease, AAT deficiency or chronic obstructive 
pulmonary disease.
MAterIAls And MetHods
DNA constructs and vector production. The AAV vectors flanked with 
AAV2 inverted terminal repeats (ITRs) contained either (i) a LacZ gene 
fused to a nucleus localization sequence at the N-terminus (nLacZ); (ii) 
an enhanced green fluorescence protein gene; or (iii) an hAAT gene under 
the transcriptional control of the cytomegalovirus–enhanced chicken-β-
actin or the cytomegalovirus promoter. All AAV sequences of natural iso-
lates were deposited in Genbank. Most wild type isolate sequences were 
previously described.24,25,37 In brief, natural AAV isolates from human and 
 nonhuman primate sources were optimized for vector production and 
gene transfer efficiency by modifying certain atypical capsid residues called 
singletons to their conserved state.32 Those particular residues were identi-
fied by structure-function analyses. Modifications were achieved by site-
directed mutagenesis (Quickchange, Stratagene, LaJolla, CA) for all but 
one of the capsid sequences and confirmed by sequencing. Rh.32.33 was 
generated by cloning a BsiWI–BbvCI restricted rh.33 fragment into AAV2/
rh.32. Novel capsid sequences were transferred from a PCR isolate into 
TOPO cloning vectors (Invitrogen, Carlsbad, CA) and then subsequently 
cloned into an AAV packaging construct by partial restriction digestion at 
the first internal cap XhoI site on the 5′ end and, depending on the orien-
tation in the TOPO plasmid, a PmeI or EcoRV blunt end digestion. AAV 
vectors were produced as previously described.37,38
Animal models. C57BL/6 mice (6–8 weeks) were purchased from Charles 
River Laboratories (Wilmington, MA) and kept at the Animal Facility of 
the Translational Research Laboratories at the University of Pennsylvania. 
Mice were anesthetized using an intraperitoneal injection of ketamine/
xylazine. Using previously described methods mice were inoculated by 
intranasal or intratracheal routes with 1011 genome copies of AAV vector 
in a final volume of 50 µl PBS as previously described.14 Control-treated 
animals received PBS only. All animal procedures were approved by 
the Institutional Animal Care and Use Committee of the University of 
Pennsylvania.
Gene expression. For nLacZ gene expression, the lungs were processed as 
previously described.14 Transduction efficiency was estimated by examining 
20 high–power (×100) fields from two cryosections spaced 200 µm apart 
and data presented as nLacZ expressing cells per ×100 field. Assessment of 
gene transfer to the nasal airway epithelium was performed as described 
previously and is presented as the total number of LacZ positive cells in 
the respiratory epithelium as quantitated in three standard cross-sections 
of nasal airway.28 For hAAT detection, serum samples were collected by 
retro-orbital bleeding and concentration determined by ELISA.25 For GFP 
expression, each image was analyzed using ImageJ software (Rasband 
1997–2006; National Institutes of Health, Bethesda, MD, http://rsb.info.
nih.gov/ij/). For each brightness value between 60 (which is above back-
ground) and 255 (the maximum value), the number of corresponding 
pixels was determined. The number of pixels was then multiplied with 
their brightness value and the products added to give a final value for GFP 
expression.
Air–liquid interface cultures of HAE. Fresh donor human tracheobronchial 
tissues were obtained from NDRI and airway epithelial cells isolated by 
the University of North Carolina at Chapel Hill Cystic Fibrosis Center Cell 
Culture Core according to published procedures.29,39 Freshly isolated airway 
epithelial cells were seeded at 250,000 per cm2 on permeable membrane 
supports (Millicells PICM 01250, 0.4 µm pore size, Millipore, Billerica, 
MA), and allowed to reach confluency, upon which the cultures were main-
tained at an air–liquid interface to allow differentiation into pseudostrati-
fied ciliated airway epithelium. The HAE cultures were maintained at an 
air–liquid interface for 4–6 weeks before  inoculation with AAV vectors.
Inoculation of cultures of HAE. For viral inoculation, the apical surfaces 
of HAE cultures were briefly rinsed with PBS to remove accumulated api-
cal secretions, followed by inoculation with 1011 genome copies (MOI = 
200,000) of candidate AAVGFP vectors in 100 µl. All AAV vector candi-
dates expressed GFP using the cytomegalovirus promoter. Virus inoculum 
was removed 2 hours later and cultures maintained at 37 °C. The extent of 
AAV-mediated GFP transduction was monitored for each of the 7 days 
after inoculation by observing GFP-positive cells using an inverted fluo-
rescent microscope, Leica DMIRB (Leica Microsystems, Bannockburn, IL, 
USA). Fluorescent photomicrographs were obtained using a color CCD 
camera (Q-Imaging RET-EXI-F-M-12C, Q-Imaging, Surrey, BC, Canada), 
and the Q-capture software. To identify transduced epithelial cell types, 
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HAE cultures were fixed in 4% paraformaldehyde and cilia immunola-
belled with a β-tubulin IV specific monoclonal antibody (Sigma, St. Louis, 
MO) and fluorescent XZ confocal images obtained with a Zeiss 510 Meta 
Laser Scanning Confocal Microscope as described previously.40
Statistical analysis. Statistical analysis was performed using the SigmaStat 
3.1 program (SPSS, Chicago, IL). Statistical significance was set at P < 0.05 
and statistical power at 0.80. Results are presented as the average of 2 sets of 
pooled samples ± SD. Student’s t-test was used for two-group comparisons 
and analysis of variance Student–Newman–Keuls test for multiple group 
comparisons.
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